结直肠癌患者中IGF2 LOI以及表达的研究  

IGF2 LOI and Expression in CRC Patients

作　　者：甘德芳[1,2] 高天翼[1] 王书奎[1] 吴华 俞胜琴 

机构地区：[1]南京医科大学附属南京医院中心实验室,江苏南京210006 [2]南京市江宁区第二人民医院检验科,江苏南京211103

出　　处：《现代生物医学进展》2013年第11期2090-2092,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81172141)

摘　　要：目的:结直肠癌(CRC)在全球范围内位居恶性肿瘤的第3位,是我国最为高发的恶性肿瘤之一。作为表观调控的一种,基因组印记丢失(LOI)被证明在结直肠癌的发生发展中具有重要的作用。本次研究通过检测结直肠癌患者中胰岛样生长因子2(IGF2)基因组印迹丢失,探讨其在结直肠癌发生及其发展的病理过程中的作用。方法:采用聚合酶链式反应-限制性酶切片段多态性(PCR-RFLP)法筛选出47名结直肠癌患者的杂合子携带者,采用RT-PCR及PCR-RFLP法检测杂合子患者中IGF2 LOI。采用荧光定量PCR检测肿瘤患者体内肿瘤组织中IGF2的表达情况。结果:在31例的杂合子中,发现有11例肿瘤组织发生LOI。对患者的年龄、性别、吸烟史、肿瘤等级以及病理分期的比较结果显示,IGF2 LOI的患者与IGF2基因印记正常的患者中未发现存在显著差异无统计学意义(P>0.05)。IGF2 LOI的患者相比较,IGF2印记正常的患者更易出现肿瘤的转移(P<0.05)。IGF2 LOI患者的IGF2表达量明显高于IGF2印记正常的患者(P<0.05)。结论:本次实验表明IGF2 LOI在结直肠癌发生发展中具有重要作用,特别是结直肠癌伴转移的患者常常表现出IGF2 LOI这一现象。IGF2 LOI可以作为一个新的表观遗传学标志,用于临床结直肠癌的早期诊断,以及肿瘤转移的评估和预防。Objective： As the third common cancer in the world,CRC is one of the most common carcinoma in China.As one of the epigenetic abnormalities,loss of imprinting has been proved to play an essential role in CRC development.To further explore the association between IGF2 LOI and CRC occurrence and development,IGF2 LOI was detected in CRC patients.Method： LOI of IGF2 was detected in 47 CRC samples,which were determined as heterozygote by PCR-RFLP and RT-PCR-RFLP.IGF2 expression was examined by real-time PCR.Results： 11 of 31 informative CRC patients showed IGF2 LOI.Patients with IGF2 LOI appeared to metastasis much more than patients with IGF2 MOI（P〈0.05）.There was no significant difference between IGF2 LOI patients and IGF2 MOI patients with respect to gender,age,cigarette,tumor differentiation or stage（P〈0.05）.IGF2 level in IGF2 LOI patients was much more than IGF2 MOI patients（P〈0.05）.Conclusion： IGF2 LOI play an important role in CRC development,especially in tumor metastasis.IGF2 LOI potentially represents a novel clinically relevant epigenetic marker to identify individuals at increased risk for CRC and the prevention of tumor metastasis.

关 键 词：结直肠癌 IGF2表达 肿瘤转移 

分 类 号：R735.37[医药卫生—肿瘤]